How to avoid making buggy whips

How to avoid making buggy whips

July 26, 2016

Manufacturers’ Monthly's first Manufacturing Leaders of Innovation event was hosted on 21 July 2016 at Trajan's Global Corporate Headquarters in Melbourne, Australia, and supported by Autodesk.

From Manufacturers' Monthly:

Innovation might be a word some are sick of, but it remains essential for success. Melbourne-based manufacturer Trajan Scientific and Medical shared a few insights into what it involves for them.

Read the full article at Manufacturers' Monthly: How to avoid making buggy whips

Dr Andrew Gooley, Chief Scientific Officer, Trajan Scientific and Medical speaking at Manufacturing Leaders of Innovation event
Photo: Dr Andrew Gooley, Chief Scientific Officer, Trajan Scientific and Medical speaking at Manufacturing Leaders of Innovation event.




Also in News

Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst

September 07, 2020

Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.

Read More

European patent for Trajan’s hemaPEN
European patent for Trajan’s hemaPEN

July 13, 2020

Trajan Scientific and Medical is proud to advise that the European Patent Office will be granting a patent for hemaPEN® as a liquid collection device in Belgium, France, Germany, Ireland, Luxembourg, Monaco, Switzerland, Liechtenstein and the United Kingdom. Extensions are being sought across the remainder of Europe.

Read More

US FDA listing of Trajan’s hemaPEN blood microsampling device
US FDA listing of Trajan’s hemaPEN blood microsampling device

July 02, 2020

Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.

Read More